The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes.
Open accessAbstract
Engagement of the CD3/T cell antigen receptor complex on small, resting T cells is insufficient to trigger cell-mediated cytotoxicity or to induce a proliferative response. In the present study, we have used genetic transfection to demonstrate that interaction of the B7-BB1 B cell activation antigen with the CD28 T cell differentiation antigen costimulates cell-mediated cytotoxicity and proliferation initiated by either anti-CD2 or anti-CD3 monoclonal antibody (mAb). Moreover, a B7-negative Burkitt's lymphoma cell line that fails to stimulate an allogeneic mixed lymphocyte response is rendered a potent stimulator after transfection with B7. The mixed leukocyte reaction proliferative response against the B7 transfectant is inhibited by either anti-CD28 or B7 mAb. We also demonstrate that freshly isolated small, resting human T cells can mediate anti-CD3 or anti-CD2 mAb-redirected cytotoxicity against a murine Fc receptor-bearing mastocytoma transfected with human B7. These preexisting cytotoxic T lymphocytes in peripheral blood are present in both the CD4 and CD8 subsets, but are preferentially within the CD45RO+ "memory" population. While small, resting T cells apparently require costimulation by CD28/B7 interactions, this requirement is lost after T cell activation. Anti-CD3 initiates a cytotoxic response mediated by in vitro cultured T cell clones in the absence of B7 ligand. The existence of functional cytolytic T cells in the small, resting T cell population may be advantageous in facilitating rapid responses to immune challenge.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Linsley, P. S., Brady, W., Grosmaire, L., Aruffo, A., Damle, N. K., & Ledbetter, J. A. (1991) · The Journal of experimental medicine · doi:10.1084/jem.173.3.721 · Cited by 1,127
Meuer, S. C., Hussey, R. E., Fabbi, M., Fox, D., Acuto, O., Fitzgerald, K. A., Hodgdon, J. C., Protentis, J. P., Schlossman, S. F., & Reinherz, E. L. (1984) · Cell · doi:10.1016/0092-8674(84)90039-4 · Cited by 1,113
Regulation of Lymphokine Messenger RNA Stability by a Surface-Mediated T Cell Activation Pathway
Lindstein, T., June, C. H., Ledbetter, J. A., Stella, G., & Thompson, C. B. (1989) · Science · doi:10.1126/science.2540528 · Cited by 878
Lanier, L. L., Le, A. M., Phillips, J. H., Warner, N. L., & Babcock, G. F. (1983) · The Journal of Immunology · doi:10.4049/jimmunol.131.4.1789 · Cited by 847
Self-citationHuman naive and memory T cells
Sanders, M. E., Makgoba, M. W., & Shaw, S. (1988) · Immunology Today · doi:10.1016/0167-5699(88)91212-1 · Cited by 781
Imboden, J. B., & Stobo, J. D. (1985) · The Journal of experimental medicine · doi:10.1084/jem.161.3.446 · Cited by 729
Phillips, J. H., & Lanier, L. L. (1986) · The Journal of experimental medicine · doi:10.1084/jem.164.3.814 · Cited by 684
Self-citationThe Role of the T3/Antigen Receptor Complex in T-Cell Activation
Weiss, A. (1986) · Annual Review of Immunology · doi:10.1146/annurev.immunol.4.1.593 · Cited by 619
B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells.
Freeman, G. J., Freedman, A. S., Segil, J. M., Lee, G., Whitman, J. F., & Nadler, L. M. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.143.8.2714 · Cited by 476
Weiss, A., Imboden, J., Shoback, D., & Stobo, J. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.13.4169 · Cited by 444
Cited by
CD28/B7 SYSTEM OF T CELL COSTIMULATION
Lenschow, D. J., Walunas, T. L., & Bluestone, J. A. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.233 · Cited by 2,717
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
The B7 and CD28 receptor families
June, C. H., Bluestone, J. A., Nadler, L. M., & Thompson, C. B. (1994) · Immunology Today · doi:10.1016/0167-5699(94)90080-9 · Cited by 1,296
Chen, L., Ashe, S., Brady, W. A., Hellström, I., Hellström, K. E., Ledbetter, J. A., McGowan, P., & Linsley, P. S. (1992) · Cell · doi:10.1016/s0092-8674(05)80059-5 · Cited by 1,050
B70 antigen is a second ligand for CTLA-4 and CD28
Azuma, M., Ito, D., Yagita, H., Okumura, K., Phillips, J. H., Lanier, L. L., & Somoza, C. (1993) · Nature · doi:10.1038/366076a0 · Cited by 909
Self-citationTabeta, K., Hoebe, K., Janssen, E. M., Du, X., Georgel, P., Crozat, K., Mudd, S., Mann, N., Sovath, S., Goode, J., et al. (2006) · Nature Immunology · doi:10.1038/ni1297 · Cited by 600
Inaba, K., Witmer-Pack, M., Inaba, M., Hathcock, K. S., Sakuta, H., Azuma, M., Yagita, H., Okumura, K., Linsley, P. S., Ikehara, S., et al. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.5.1849 · Cited by 592
Self-citationRanheim, E. A., & Kipps, T. J. (1993) · The Journal of experimental medicine · doi:10.1084/jem.177.4.925 · Cited by 580
Apoptotic signaling through CD95 (Fas/Apo-1) activates an acidic sphingomyelinase.
Cifone, M. G., De Maria, R., Roncaioli, P., Rippo, M. R., Azuma, M., Lanier, L. L., Santoni, A., & Testi, R. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.4.1547 · Cited by 573
Self-citationT-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo.
Turka, L. A., Linsley, P. S., Lin, H., Brady, W., Leiden, J. M., Wei, R. Q., Gibson, M. L., Zheng, X. G., Myrdal, S., & Gordon, D. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.22.11102 · Cited by 533
Tan, P., Anasetti, C., Hansen, J. A., Melrose, J., Brunvand, M., Bradshaw, J., Ledbetter, J. A., & Linsley, P. S. (1993) · The Journal of experimental medicine · doi:10.1084/jem.177.1.165 · Cited by 461
Chambers, C. A., Sullivan, T. J., & Allison, J. P. (1997) · Immunity · doi:10.1016/s1074-7613(00)80406-9 · Cited by 411
Expansion of cytotoxic CD8 + CD28 − T cells in healthy ageing people, including centenarians
FAGNONI, F. F., VESCOVINI, R., MAZZOLA, M., BOLOGNA, G., NIGRO, E., LAVAGETTO, G., FRANCESCHI, C., PASSERI, M., & SANSONI, P. (1996) · Immunology · doi:10.1046/j.1365-2567.1996.d01-689.x · Cited by 362
Murphy, E. E., Terres, G., Macatonia, S. E., Hsieh, C. S., Mattson, J., Lanier, L., Wysocka, M., Trinchieri, G., Murphy, K., & O'Garra, A. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.1.223 · Cited by 360
Self-citationPivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity
Guinan, E., Gribben, J., Boussiotis, V., Freeman, G., & Nadler, L. (1994) · Blood · doi:10.1182/blood.v84.10.3261.3261 · Cited by 358
Kelleher, A. D., Carr, A., Zaunders, J., & Cooper, D. A. (1996) · Journal of Infectious Diseases · doi:10.1093/infdis/173.2.321 · Cited by 323
Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cell
Miyashita, E. M., Yang, B., Babcock, G. J., & Thorley-Lawson, D. A. (1997) · Journal of Virology · doi:10.1128/jvi.71.7.4882-4891.1997 · Cited by 306
The Binding and Lysis of Target Cells by Cytotoxic Lymphocytes: Molecular and Cellular Aspects
Berke, G. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.003511 · Cited by 305
Functional expression of the costimulatory molecule, B7/BB1, on murine dendritic cell populations.
Larsen, C. P., Ritchie, S. C., Pearson, T. C., Linsley, P. S., & Lowry, R. P. (1992) · The Journal of experimental medicine · doi:10.1084/jem.176.4.1215 · Cited by 302
What's the difference between CD80 and CD86?
Sansom, D. M., Manzotti, C. N., & Zheng, Y. (2003) · Trends in Immunology · doi:10.1016/s1471-4906(03)00111-x · Cited by 289
Kanamaru, F., Youngnak, P., Hashiguchi, M., Nishioka, T., Takahashi, T., Sakaguchi, S., Ishikawa, I., & Azuma, M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.12.7306 · Cited by 285
Self-citationMagistrelli, G., Jeannin, P., Herbault, N., Benoit de Coignac, A., Gauchat, J.-F., Bonnefoy, J.-Y., & Delneste, Y. (1999) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199911)29:11<3596::aid-immu3596>3.0.co;2-y · Cited by 276
Functional expression of B7/BB1 on activated T lymphocytes.
Azuma, M., Yssel, H., Phillips, J. H., Spits, H., & Lanier, L. L. (1993) · The Journal of experimental medicine · doi:10.1084/jem.177.3.845 · Cited by 267
Self-citationHarding, F. A., & Allison, J. P. (1993) · The Journal of experimental medicine · doi:10.1084/jem.177.6.1791 · Cited by 265
Physical and Functional Association of LFA-1 with DNAM-1 Adhesion Molecule
Shibuya, K., Lanier, L. L., Phillips, J. H., Ochs, H. D., Shimizu, K., Nakayama, E., Nakauchi, H., & Shibuya, A. (1999) · Immunity · doi:10.1016/s1074-7613(00)80136-3 · Cited by 260
Self-citationVISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy
Lines, J. L., Sempere, L. F., Broughton, T., Wang, L., & Noelle, R. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0072 · Cited by 236
“CD80 or CD86, it facilitates fulminant T-cell activation (4, 5).”
Tacke, M., Hanke, G., Hanke, T., & Hünig, T. (1997) · European Journal of Immunology · doi:10.1002/eji.1830270136 · Cited by 163
Gastrointestinal toxicity of immune checkpoint inhibitors: From mechanisms to management
Samaan, M. A., Pavlidis, P., Papa, S., Powell, N., & Irving, P. M. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2018.14 · Cited by 100
Zhang, W., Jordan, K. R., Schulte, B., & Purev, E. (2018) · Drug Design, Development and Therapy · doi:10.2147/dddt.s175113 · Cited by 60
Metadata
- Authors
- Azuma, M., Cayabyab, M., Buck, D., Phillips, J. H., & Lanier, L. L.
- Venue
- The Journal of experimental medicine
- Publisher
- Rockefeller University Press
- Published
- 1992-02-01
- Volume
- 175
- Issue
- 2
- Pages
- 353-360
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2158787913
- Cited by
- 318
- References
- 38
- FWCI
- 15.34
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.